Document Detail


Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors.
MedLine Citation:
PMID:  17255142     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Liver toxicity is one of the most relevant adverse effects of antiretroviral therapy. Within the non-nucleoside reverse transcriptase inhibitors (NNRTIs), efavirenz can be considered a safer drug for the liver than nevirapine. In fact, the frequency of severe increased liver enzymes in patients on efavirenz ranges from 1 to 8%, whereas in patients treated with nevirapine, it ranges from 4 to 18%. Likewise, nevirapine is more commonly associated than efavirenz with early acute hepatitis, which is produced by a hypersensitivity mechanism and has a defined risk profile that often makes it avoidable. Despite the fact that most cases of NNRTI-induced liver toxicity are asymptomatic, the rates of symptomatic events in patients treated with nevirapine are greater than in subjects on efavirenz. In any case, it is unusual for an NNRTI to be suspended due to liver toxicity.
Authors:
Antonio Rivero; José A Mira; Juan A Pineda
Publication Detail:
Type:  Journal Article; Review     Date:  2007-01-25
Journal Detail:
Title:  The Journal of antimicrobial chemotherapy     Volume:  59     ISSN:  0305-7453     ISO Abbreviation:  J. Antimicrob. Chemother.     Publication Date:  2007 Mar 
Date Detail:
Created Date:  2007-02-27     Completed Date:  2007-05-11     Revised Date:  2014-02-06    
Medline Journal Info:
Nlm Unique ID:  7513617     Medline TA:  J Antimicrob Chemother     Country:  England    
Other Details:
Languages:  eng     Pagination:  342-6     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Alanine Transaminase / blood
Anti-HIV Agents / adverse effects*
Aspartate Aminotransferases / blood
Benzoxazines / adverse effects*
Drug Hypersensitivity
Drug-Induced Liver Injury / etiology
Humans
Liver / drug effects*,  enzymology
Nevirapine / adverse effects*
Reverse Transcriptase Inhibitors / adverse effects*
Risk Factors
Chemical
Reg. No./Substance:
0/Anti-HIV Agents; 0/Benzoxazines; 0/Reverse Transcriptase Inhibitors; 99DK7FVK1H/Nevirapine; EC 2.6.1.1/Aspartate Aminotransferases; EC 2.6.1.2/Alanine Transaminase; JE6H2O27P8/efavirenz

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Reasons for discontinuation of nevirapine-containing HAART: results from an unselected population of...
Next Document:  Rifampicin-impregnated central venous catheters: a meta-analysis of randomized controlled trials.